Comments
Aurobindo Pharma’s subsidiary, Eugia Pharma, has received USFDA approval for Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial. The approval allows Eugia Pharma to manufacture and market a bioequivalent and therapeutically equivalent product to Mozobil Injection by Genzyme Corporation.
Plerixafor injection is indicated for mobilising hematopoietic stem cells in patients with non-Hodgkin’s lymphoma or multiple myeloma. The product’s launch is scheduled for July FY24, and it holds an estimated market size of approximately US$210 million based on IQVIA data for the 12 months ending May 2023. This approval marks the 163rd ANDA received by Eugia Pharma Speciality Group.
Also read: Eugia Pharma gets USFDA nod for Vasopressin injection
The shares of Aurobindo Pharma went up by 0.10 per cent to Rs 785 at 02:04 p.m. on BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.